OPL-0101
/ Valo Health
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 02, 2022
Valo Health Announces Publication of the Journal of Clinical Investigation of a New Therapeutic Approach to Improve CD8+ T Cell Function
(PRNewswire)
- "The data presented in JCI demonstrates that OPL-0101 (referred to as OMCPmutIL-2 in the paper) triggers improved CD8+ T cell function by utilizing a novel signaling pathway different from any currently available immunotherapy...The preclinical research found that in both murine and human CD8+ T cells, OPL-0101 improved CD8+ T cell viability, increased memory cell generation, and decreased exhaustion."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1